Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Childhood cancers1 trial
• Gastric and oesophageal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Multiple sclerosis1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed2 trials
• Active, not recruiting1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• EMD Serono Research & Development Institute, Inc.2 trials
• Biogen1 trial
• Daiichi Sankyo1 trial
• Taiho Oncology, Inc.1 trial

Running trials

• Recruiting

  Met Non Small Cell Cancer Registry (MOMENT)

  NCT05376891· EMD Serono Research & Development Institute, Inc.· Source

  Contact: Antonio Araujo (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

  NCT03958877· Phase 3· Biogen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting

Closed trials

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Taiho Oncology, Inc.· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source